Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
arcticnovartis
Sat, 05/25/2024 – 12:04
Read more about Nov…